DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.

Also called NCT07322237

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07322237
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
India (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07322237. Randomized; quadruple masking; primary purpose treatment. Start 2026-04-01 (actual); primary completion 2029-01-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
Acronym
DICE
Condition
Cirrhotic Cardiomyopathy
Condition
Empagliflozin
Condition
Cardiometabolic Risk Factors
Condition
Cirrhosis
Intervention (Drug)
Empagliflozin + Carvedilol
Intervention (Drug)
Carvedilol
Lead sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh (class: other)

Record details

Record id
cardio:ct-nct07322237
Content hash
35a30ab5cdc07f2be821113a454e4bb28832f7271a46c04e1eed2399e8e4ef2a